GENMAB A/S (GE9.DE) Forecast, Price Target & Analyst Ratings

FRA:GE9 • DK0010272202

235.9 EUR
-4.4 (-1.83%)
Last: Mar 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GENMAB A/S (GE9.DE).

Forecast Snapshot

Consensus Price Target

Price Target
€307.95
+ 30.54% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release DateMay 7, 2026
PeriodQ1 / 2026
EPS Estimate$2.46
Revenue Estimate928.95M
 → Full earnings forecast details

ChartMill Buy Consensus

Rating
73.85%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€307.95
Upside
+ 30.54%
From current price of €235.90 to mean target of €307.95, Based on 26 analyst forecasts
Low
€177.05
Median
€316.34
High
€427.16

Price Target Revisions

1 Month
3.56%
3 Months
6.01%

Price Target Summary

26 Wall Street analysts provided a forecast for the next 12 months for GE9.DE. The average price target is 307.95 EUR. This implies a price increase of 30.54% is expected in the next year compared to the current price of 235.9.
The average price target has been revised upward by 6.01% in the past 3 months.
 → Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

GE9 Current Analyst RatingGE9 Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

GE9 Historical Analyst RatingsGE9 Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 10 20 30

Analyst Ratings Consensus

ChartMill Buy Consensus
73.85%
GE9.DE was analyzed by 26 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about GE9.DE.
In the previous month the buy percentage consensus was at a similar level.
GE9.DE was analyzed by 26 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release DateMay 7, 2026
PeriodQ1 / 2026
EPS Estimate$2.46
Revenue Estimate928.95M
Revenue Q2Q29.92%
EPS Q2Q-19.20%
Number of Analysts9

Next Earnings Revisions

Revenue (1 Month)
0.88%
Revenue (3 Months)
0.88%
EPS (1 Month)
-34.20%
EPS (3 Months)
-34.20%

Next Earnings Summary

GE9.DE is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 2.46 EUR and the consensus revenue estimate is 928.95M EUR.
The next earnings revenue estimate has been revised upward by 0.88% in the past 3 months.
 → Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
GE9.DE revenue by date.GE9.DE revenue by date.
2.391B
16.63%		3.122B
30.57%		3.72B
19.15%		4.382B
17.80%		5.033B
14.86%		5.94B
18.02%		6.497B
9.38%		6.781B
4.37%		6.784B
0.04%		6.715B
-1.02%		7.175B
6.85%
EBITDA
YoY % growth
GE9.DE ebitda by date.GE9.DE ebitda by date.
815.128M
-13.49%		1.087B
33.30%		1.339B
23.23%		1.295B
-3.29%		1.699B
31.20%		2.24B
31.84%		2.523B
12.63%		1.657B
-34.32%		1.996B
20.46%		1.75B
-12.32%		2.249B
28.51%
EBIT
YoY % growth
GE9.DE ebit by date.GE9.DE ebit by date.
772.311M
-13.33%		1.027B
32.94%		1.268B
23.50%		1.269B
0.08%		1.614B
27.19%		2.214B
37.17%		2.116B
-4.43%		2.178B
2.93%		2.16B
-0.83%		2.145B
-0.69%		2.376B
10.77%
Operating Margin
GE9.DE operating margin by date.GE9.DE operating margin by date.
32.30%32.89%34.09%28.96%32.07%37.27%32.57%32.12%31.84%31.94%33.11%
EPS
YoY % growth
GE9.DE eps by date.GE9.DE eps by date.
9.62
-17.57%		17.52
82.09%		17.06
-2.61%		14.49
-15.07%		18.87
30.22%		27.99
48.37%		26.26
-6.18%		27.32
4.04%		29.88
9.35%		29.74
-0.48%		33.30
11.97%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		2.46
-19.20%		3.40
-37.29%		5.92
-8.34%		5.69
167.05%
Revenue
Q2Q % growth		928.95M
29.92%		1.125B
21.62%		1.178B
15.26%		1.186B
12.10%
EBITDA
Q2Q % growth		246.1M
20.64%		290.45M
-25.91%		664.45M
30.54%		N/A
EBIT
Q2Q % growth		177.12M
-5.79%		295.5M
-17.92%		523.54M
14.06%		523.81M
115.56%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GE9.DE Yearly Revenue VS EstimatesGE9.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GE9.DE Yearly EPS VS EstimatesGE9.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
17.95%
EPS Next 5 Year
9.88%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
17.06%
Revenue Next 5 Year
12.86%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
19.49%
EBIT Next 5 Year
4.76%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

GENMAB A/S / GE9.DE Forecast FAQ

What do analysts expect the price target to be for GENMAB A/S (GE9.DE)?

26 analysts have analysed GE9.DE and the average price target is 307.95 EUR. This implies a price increase of 30.54% is expected in the next year compared to the current price of 235.9.


Can you provide the upcoming earnings date for GENMAB A/S?

GENMAB A/S (GE9.DE) will report earnings on 2026-05-07.


What are the consensus estimates for GENMAB A/S (GE9.DE) next earnings?

The consensus EPS estimate for the next earnings of GENMAB A/S (GE9.DE) is 2.46 EUR and the consensus revenue estimate is 928.95M EUR.


How many analysts cover GENMAB A/S (GE9.DE) stock?

The number of analysts covering GENMAB A/S (GE9.DE) is 26.